135 related articles for article (PubMed ID: 29182642)
41. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
42. Usefulness of bone resorption markers in hemodialysis patients.
Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y
Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165
[TBL] [Abstract][Full Text] [Related]
43. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
44. Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
Teng X; Wei L; Han L; Min D; Du Y
BMC Cancer; 2020 Jun; 20(1):562. PubMed ID: 32546271
[TBL] [Abstract][Full Text] [Related]
45. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
46. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer.
Kiuchi K; Ishikawa T; Hamaguchi Y; Momiyama N; Hasegawa S; Ishiyama A; Kono T; Doi T; Chishima T; Shimada H
Oncol Rep; 2002; 9(3):595-8. PubMed ID: 11956634
[TBL] [Abstract][Full Text] [Related]
47. [Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases].
Wu CJ; Ma LX; Zhu J; Liu JJ; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):693-7. PubMed ID: 27647403
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
49. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
[TBL] [Abstract][Full Text] [Related]
50. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
51. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients.
Imamura M; Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Sakita I; Hatada T; Takatsuka Y; Katagiri T; Miyoshi Y
Breast Cancer Res Treat; 2015 Dec; 154(3):521-31. PubMed ID: 26573829
[TBL] [Abstract][Full Text] [Related]
52. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
53. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
[TBL] [Abstract][Full Text] [Related]
54. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
[TBL] [Abstract][Full Text] [Related]
55. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
56. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
[TBL] [Abstract][Full Text] [Related]
57. Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer.
Tanaka Y; Yoshimasu T; Oura S; Hirai Y; Kawago M; Ikeda M; Okamura Y
Eur J Cardiothorac Surg; 2013 Sep; 44(3):539-43; discussion 543. PubMed ID: 23435520
[TBL] [Abstract][Full Text] [Related]
58. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
59. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
60. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]